Tildren® (tiludronate disodium) Reduces Bone Resorption

The active ingredient in Tildren® is tiludronate disodium, a bisphosphate that achieves its effect by regulating osteoclasts in areas of excessive activity. Following IV infusion, Tildren® travels through the blood stream and binds to the mineral matrix of the bone. The acidity of the remodeling environment causes the release of Tildren® from the bone matrix to the resorption space. This leads to improved bone remodeling, decreased mineral loss and alleviation of pain induced by abnormal osteolysis.


Learn More About How Tildren® Works

  1. Tildren® binds preferentially to the mineral phase of the bone at remodeling sites.
  2. Acidification breaks the bond.
  3. Tildren® is taken into the osteoclast by endocytosis.
how circles

See How Tildren® Works

Product Efficacy

Tildren® (tiludronate disodium) given at 1mg/kg IV, in conjunction with corrective shoeing, proved to be more effective in controlling clinical signs associated with navicular syndrome when evaluated at two months post-treatment compared to corrective shoeing alone.1

1 Freedom of Information Summary. NADA #141-420. Approved February 13, 2014.

imagehow graph bm

Do not use in horses with impaired renal function or with a history of renal disease. NSAIDs should not be used concurrently with TILDREN®. Concurrent use of NSAIDs with TILDREN® may increase the risk of renal toxicity and acute renal failure. Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions.

Caution should be used when administering TILDREN® to horses with conditions affecting mineral or electrolyte homeostasis (e.g. HYPP, hypocalcemia) and conditions which may be exacerbated by hypocalcemia (e.g. cardiac disease). The safe use of TILDREN® has not been evaluated in horses less than 4 years of age, in pregnant or lactating mares, or in breeding horses. See package insert for full prescribing information.